- Home
- SENEA vs KURA Comparison
SENEA vs KURA Comparison
Compare SENEA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- KURA
- Stock Information
- Founded
- SENEA 1949
- KURA 2014
- Country
- SENEA United States
- KURA United States
- Employees
- SENEA N/A
- KURA N/A
- Industry
- SENEA Packaged Foods
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SENEA Consumer Staples
- KURA Health Care
- Exchange
- SENEA Nasdaq
- KURA Nasdaq
- Market Cap
- SENEA 595.0M
- KURA 592.7M
- IPO Year
- SENEA N/A
- KURA N/A
- Fundamental
- Price
- SENEA $88.49
- KURA $6.64
- Analyst Decision
- SENEA
- KURA Strong Buy
- Analyst Count
- SENEA 0
- KURA 10
- Target Price
- SENEA N/A
- KURA $25.50
- AVG Volume (30 Days)
- SENEA 32.4K
- KURA 1.2M
- Earning Date
- SENEA 02-06-2025
- KURA 05-01-2025
- Dividend Yield
- SENEA N/A
- KURA N/A
- EPS Growth
- SENEA 25.61
- KURA N/A
- EPS
- SENEA 5.45
- KURA N/A
- Revenue
- SENEA $1,541,031,000.00
- KURA $53,883,000.00
- Revenue This Year
- SENEA N/A
- KURA $13.15
- Revenue Next Year
- SENEA N/A
- KURA $221.86
- P/E Ratio
- SENEA $16.58
- KURA N/A
- Revenue Growth
- SENEA 4.00
- KURA N/A
- 52 Week Low
- SENEA $51.79
- KURA $6.79
- 52 Week High
- SENEA $90.35
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- SENEA 60.41
- KURA 34.25
- Support Level
- SENEA $84.41
- KURA $6.95
- Resistance Level
- SENEA $88.91
- KURA $8.04
- Average True Range (ATR)
- SENEA 2.37
- KURA 0.43
- MACD
- SENEA -0.05
- KURA -0.04
- Stochastic Oscillator
- SENEA 70.31
- KURA 4.17
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.